Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
217330
vs
K
KOSPI 200
Over the past 12 months, Cytogen Inc has underperformed KOSPI 200, delivering a return of -11% compared to KOSPI 200's +125% growth.
Stocks Performance
217330 vs KOSPI 200
Performance Gap
217330 vs KOSPI 200
Performance By Year
217330 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cytogen Inc
Glance View
Cytogen Inc makes diagnostic products used to test samples in medical laboratories. Its business is built around reagents, test kits, and related lab instruments that help doctors and labs detect disease or analyze biological material. In simple terms, it sells the tools that let hospitals and testing centers run specialized medical tests. Its main customers are hospitals, clinics, laboratories, and other healthcare organizations that need reliable lab testing products. Cytogen makes money by selling consumable test reagents and kits, along with any instruments or equipment tied to those tests. Like many diagnostics companies, it benefits when customers keep buying the same test materials over time, because those consumables must be reordered regularly. What makes the business model specific is that it sits in the medical testing supply chain, not in direct patient care. Cytogen’s value comes from turning scientific testing methods into practical products that laboratories can use every day. That puts it in a niche where technical quality, test accuracy, and regulatory compliance matter more than broad consumer branding.